MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a strategic focus on industrial safety applications in South America’s mining sector. The company recently appointed Chilean drug policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a targeted push into an industry employing over 200,000 workers in Chile alone.
MindBio’s technology analyzes voice patterns to detect intoxication or impairment without the need for biological testing. The platform is designed as a scalable tool for workplace safety in mining and other high-risk industries. Management has outlined plans to begin deploying the system in industrial environments starting in 2026, with Chile’s mining sector serving as an early target market.
The move comes as the company also closed an upsized non-brokered private placement of up to $1.5 million to support commercialization activities. This financing is expected to accelerate the development and deployment of the voice-based impairment detection system.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection. The company’s approach offers a non-invasive, rapid screening method that could improve safety protocols in industries where impairment poses significant risks.
According to the company, the appointment of Felipe Leyton, a specialist in Chilean drug policy, underscores its commitment to navigating local regulatory landscapes and building partnerships within the mining industry. The mining sector in Chile is a cornerstone of the national economy, and safety compliance is a critical concern for operators.
For more information on MindBio Therapeutics, visit the company’s newsroom at https://ibn.fm/MBQIF.
BioMedWire (BMW) is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. BMW is where breaking news, insightful content and actionable information converge.
